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Renal regenerationAbstract Introduction: Chronic allograft nephropathy (CAN) is a poorly understood clinico-path-
ological entity associated with chronic allograft loss due to immunologic and non-immunologic
causes. It remains the leading cause of late allograft loss. Bonemarrow derived stem cells are undiffer-
entiated cells typically characterized by their capacity for self renewal, ability to give rise to multiple
differentiated cellular population, including hematopoietic (HSCs) and mesenchymal stem cells
(MSCs). Characterization of HSCs includes their multipotency, expression of typical surface markers
such as CD34 and CD45, while characterization of MSC includes their multipotency, expression of
typical surface markers such as CD90 and CD105, and the absence of hemopoietic lineage markers.
Aim&methods: The aim of the present workwas to study the role of bonemarrow-derivedHSCs and
MSCs, renal progenitor cells and SCF in chronic renal allograft nephropathy in relation to renal
hemodynamics and histopathological changes. We studied 30 patients with kidney transplantation
for more than 6 months, divided into 15 patients with stable serum creatinine and 15 patients who
developed CAN. Detection of HSCs and MSCs in the peripheral blood using ﬂow cytometry via
detection of CD34, CD45, CD117 and CD106, as well as immunohistochemical detection of CD34,
CD133, VEGF and aSMA in transplanted kidney biopsies of patients with CAN were done.
Results: There was a signiﬁcant increase in the levels of SCF, number of peripheral blood HSCs and
MSCs in both transplanted patient groups than the controls and they were higher in patients of group
Ia than patients of group Ib, (F= 39.73, P< 0.001), (F= 13.28, P< 0.001), (F= 11.94,
P< 0.001), respectively and this was accompanied by evident expression of markers of renal repair.
Conclusion: Stem cells might have a role in renal regeneration in CAN and this may pave the way
toward the use of stem cells in correction of CAN.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Alexandria University Faculty of Medicine.1. Introduction
Chronic allograft dysfunction (CAD) is a clinico-pathological
entity associated with chronic allograft loss caused by immu-
nologic and non-immunologic causes.1
Chronic allograft injury is the leading cause of late graft
loss after kidney transplantation2 characterized by progressive
interstitial ﬁbrosis and tubular atrophy (IF/TA) as well as
microvascular and glomerular damage accompanied by declin-
ing graft function months to years after transplantation.3
In spite that the incidence of acute rejection and early graft
failure had declined dramatically as a result of development in
immunosuppressive medications and protocols, and the one
year graft survival is now close to 90% in most transplant cen-
ters, yet, late allograft failure remains the problem to
overcome.4
Signiﬁcant attention has been directed to study the potenti-
ality of stem cells (SCs) in the treatment of a number of acute
and chronic diseases.5,6
The bone marrow (BM) derived SCs are undifferentiated
cells typically characterized by its capacity for self renewal,
ability to give rise to multiple differentiated cellular popula-
tions (often termed cellular plasticity)7 and the ability to gen-
erate many if not all of the differentiated cell types that are
contained in an organ,8 so that in the presence of damage,
these cells can replace the injured ones.9 The BM harbors
two distinct stem cell populations: hematopoietic stem cells
(HSCs)10 and mesenchymal stem cells (MSCs), which provide
stromal support for HSCs.11
The bone marrow derived HSCs, are pluripotent undiffer-
entiated cells that give rise to all blood cells (erythrocytes,
thrombocytes, and leukocytes) and move between the bone
marrow and the peripheral blood. The CD34 antigen is highly
expressed in pluripotent cells and its expression gradually re-duces as the level of maturation of hematopoietic cell lineages
increases, to the point of becoming completely absent in fully
mature cells. HSCs can be mobilized into the circulation in re-
sponse to multiple cytokines, chemokines and adhesion
molecules.12,13
Stem cell factor (SCF), also known as Steel factor or c-kit
ligand, is a cytokine produced by stromal cells and is impor-
tant for mobilization, proliferation and differentiation of
HSCs, speciﬁcally myeloerythroid lineages. SCF functions by
binding to CD117/c-Kit, a tyrosine kinase receptor, highly
expressed on HSCs.14 The SCF/c-Kit signaling pathway
promotes cell survival by inhibition of apoptosis in multiple
cell types, including HSCs. Interestingly; HPCs express the
HSC marker CD34 and SCF and its receptor c-kit.15
The other BM derived SCs are the MSCs. MSCs are plurip-
otent stromal cells which are deﬁned by their plastic adherence,
surface marker expression of CD73, CD90, CD105 and CD106
(vascular cell adhesion molecule [VCAM]-1) combined with a
lack in expression of hematopoietic markers CD34, CD45,
CD14 and HLADR, and the capacity to differentiate into cells
of mesodermal lineage including adipocytes, osteocytes, chon-
drocytes and myocytes.16
The MSCs during tissue injury, can be released from their
niche in the BM into circulation and recruited to sites of
inﬂammation by migrating toward inﬂammatory chemokines
and cytokines where they differentiate into specialized cells
and promote local tissue repair by preventing apoptosis and/
or control of inﬂammation in situ through secretion of growth
factors and cytokines and activation of endogenous progenitor
cells.17 MSCs are potent immunomodulators of both the in-
nate and adaptive immune systems.18 MSCs have been shown
to exert a profound inhibitory effect on T cell proliferation and
function. MSCs can regulate an innate immune response by
signaling dendritic cells to direct an anti-inﬂammatory T-cell
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functions. MSCs also affect an adaptive immune response by
exerting their immunoregulative effects through direct interac-
tion with T-cells. Also, MSCs can inhibit B lymphocytes’
proliferation.19
Moreover, MSCs have the ability to differentiate into
vascular cell types and release proangiogenic factors such as
vascular endothelial growth factor, which can promote the
recruitment of endothelial cells for angiogenesis.20
The immune-privileged properties attributed to MSCs
make them a powerful tool that could be used in many inﬂam-
matory and immune-mediated diseases.21
The identiﬁcation of SCs both inside the kidney pave the
way toward the future regeneration of the damaged kidney.22
There is evidence of engraftment and differentiation of stem
cells during normal renal cellular turnover,23 acute kidney in-
jury (AKI), chronic kidney disease (CKD) and in different
forms of acute and chronic glomerular diseases.24–26
So, the aim of this study was undertaken to investigate the
role of bone marrow-derived HSCs and MSCs, renal progeni-
tor cells and SCF in chronic renal allograft dysfunction in rela-
tion to renal hemodynamics and histopathological changes.
1.1. Subjects
The present study included 45 subjects who are divided into
the following groups:
Group I 30 Patients with renal transplantation who were
transplanted at the Nephrology and Transplantation Unit,
Main Alexandria University Hospital. They were subdi-
vided into two subgroups.
Group Ia 15 Patients with renal transplantation and with
biopsy proven chronic allograft nephropathy (CAN). Their
ages ranged between 17 and 54 years with a mean
33.33± 11.02 years.
Group Ib 15 Patients with renal transplantation and with
stable allograft function. Their ages ranged between 22
and 50 years with a mean 29.07 ± 7.85 years.
Group II A control group of 15 healthy subjects with
matched age and sex. Their ages ranged between 18 and
41 years with a mean 28.67 ± 6.58 years.
The study included patients transplanted for more than six
months and seronegative for hepatitis B, C, cytomegalovirus
(CMV) and human immunodeﬁciency (HIV) virus. Patients
with chronic diseases such as diabetes mellitus, connective tis-
sue diseases or other autoimmune diseases, infections or any
kind of malignancy, cardiac and respiratory diseases were ex-
cluded. None of the patients had history of previous renal
transplantation.
The study was conducted in accordance with the ethical
guidelines of the 1975 Declaration of Helsinki and an informed
consent was obtained from each patient and control in the
study.
2. Methods
All patients and controls were subjected to thorough history
taking which included previous diseases, original renal disease,
complications after transplantation, e.g. infection or rejectionincluding duration of rejection and number of attacks. Also,
a complete physical examination was done with special obser-
vation for signs of rejection including tender graft, change in
blood pressure and urine volume.
Laboratory investigations included hemoglobin concentra-
tion, total white blood count, lymphocyte count,27 renal function
tests (blood urea, serum creatinine, and creatinine clearance),28
and complete urine analysis with measurement of 24-h urinary
albumin excretion (UAE).28 Serum C-reactive protein (CRP)
measurement was done by turbidimetry.29,30 Estimation of uri-
nary alkaline phosphatase (U.ALP), as a marker of tubular func-
tion, was done by the spectrophotometric method.31
Radiological study for the assessment of the renal allograft
was done by ultrasound examination as regards the graft size,
cortical echogenicity, parenchymal thickness, corticomedullary
differentiation, and the presence of hydronephrosis or lympho-
cele. Renal hemodynamic study of the graft was measured by
duplex Doppler ultrasonography, with calculation of the resis-
tive and pulsatility indices (RI, PI).32,33
2.2. SCF assay:34
Detection of serum level of SCF was done using enzyme linked
immunosorbant assay (ELISA) kit as described by Galli.34
2.3. Enumeration of hemopoeitic and mesenchymal stem cells in
the peripheral blood by ﬂow cytometry35–37
The HSCs (CD34 + 117 + 45+) and MSCs (CD106 + 34)
in the peripheral blood are detected using 3-color ﬂow cyto-
metric assay.35 The detailed characterization of hematopoietic
stem cells was obtained by analyzing the expression of a given
set of antigens in a cell population.
Monoclonal Antibodies (MoAbs) used are: Fluorescein iso-
thiocyanate (FITC)-conjugated anti-CD45, Phycoerythrin
(PE)-conjugated anti-CD34 and Phycoerythrin (PE)-conju-
gated anti-CD117 (c-Kit) mAbs for identiﬁcation of HSCs,
(eBiosciences. Inc),36 and PE-conjugated anti-CD34 and
FITC conjugated anti-CD106 mAbs for the identiﬁcation
of MSCs (eBiosciences Inc).37 The ﬂow cytometer used was
Becton Dickinson, FACS caliber ﬂow cytometer equipped
with Cell Quest software. The procedure was done as shown
by Gajkowska, et al.35
2.4. Histopathological examination
An ultrasound guided renal biopsy was done to all patients
who were clinically suspected to have CAN (Group Ia). Biopsy
was subjected to:
2.4.1. Light microscopic examination:38
A routine light microscopic examination using variant stains
(H&E, Masson Trichrome, PAS, Silver methanamine stains)
was performed. The pathological report did describe the occur-
rence and staging of CAN according to Banff classiﬁcation
2009.392.4.2. Immunohistochemical Staining:40–43
All sections were mounted on glass slides and subjected to
monoclonal antibody staining for the following antibodies:
Table 1 Mean ± SD and statistical comparison of age, hemoglobin concentration, blood urea, serum creatinine, creatinine clearance
and urinary proteins, serum C-reactive protein, urinary alkaline phosphatase in the studied groups.
Parameters Group Ia Group Ib Group II F P L S D
GIa/GIb GIa/GII GIb/ GII
Age (years) 33.33 ± 11.02 29.07 ± 7.85 28.67 ± 6.58 1.33 0.28 NS NS NS
Bld. Hb (g/dl) 10.4 ± 1.29 12 ± 93 13.42 ± 1.15 26.55 <0.001 * * *
Bld. Urea (mg/dl) 92.67 ± 47.98 30.93 ± 6.79 27.27 ± 5.05 25.60 <0.001 * * NS
S. Cr (mg/dl) 2.67 ± 1.12 1.07 ± 0.17 0.97 ± 0.17 31.32 <0.001 * * NS
Cr. Cl (ml/min) 44.73 ± 9.74 68.00 ± 4.24 113.00 ± 15.06 159.52 <0.001 * * *
U. Pr (mg/24hs) 1348.00 ± 999.19 194.00 ± 82.10 19.22 ± 6.84 23.34 <0.001 * * NS
S. CRP (mg/l) 17.40 ± 11.34 6.73 ± 3.01 3.40 ± 1.29 17.260 <0.001 * * NS
U. ALP (umol/min) 0.06 ± 0.03 0.09 ± 0.02 0.10 ± 0.06 6.230 0.004 * * NS
Group Ia = Renal transplant patients with chronic allograft dysfunction, Group Ib = renal transplant patients with stable allograft function,
Group II = control subjects Bld. Hb = blood hemoglobin, S. Cr = serum creatinine, Cr. Cl = creatinine clearance, U. Pr = urinary protein,
S. CRP = serum C-reactive protein, U. ALP = urinary alkaline Phosphatase.
* = Signiﬁcant P value at 5% level, NS = insigniﬁcant difference between the 2 groups.
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Figure 1A Serum creatinine (mg/dl) in patients in renal
transplant recipients with chronic allograft dysfunction (Group
Ia), stable allograft function (Group Ib) and in controls (Group
II).
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Figure 1B C-reactive protein (mg/l) in patients in renal trans-
plant recipients with chronic allograft dysfunction (Group Ia),
stable allograft function (Group Ib) and in controls (Group II).
238 H.A.M. El Aggan et al.CD133 as a marker for renal progenitor cells, CD34 as stem
cell marker, vascular endothelial growth factor (VEGF) as
vascular markers, alpha smooth muscle actin (ASMA) as
ﬁbrotic marker. The four antibodies were provided by lab
vision incorporation (Neo Markers, Fremont, USA). Expres-
sion of all antibodies used was visualized using the strep-
tovodin-biotin-immunoenzymatic antigen detection system
which was performed according to manufacturers’ protocol
provided by labvision incorporation (Neo Markers, Fremont,
USA). Using standard Immunohistochemical techniques as
brieﬂy described by Ramani et al.40 for CD34, and Yin et
al.41 for CD133, Tyrley, et al.42 for VEGF and Skalli, et al.43
for aSMA
2.5. Statistical analysis
All calculations were performed on a personal computer with
SPSS software (version 11.0) for Windows (SPSS Inc., Chi-
cago, IL, USA). Qualitative data were presented as numbers
(n) and percentages (%). Quantitative data were presented as
means and standard deviation (SD). Comparison between
the means of quantitative variables was performed using
the one-way ANOVA (F-test) for comparison between three
means. The correlations between different variables were
evaluated by Pearson or Spearman correlation coefﬁcients
according to the distribution of variables (continuous or dis-
continuous quantitative variables respectively). A value
60.05 was accepted as statistically signiﬁcant.
3. Results
3.1. Clinical data
In the present study, in group Ia, 3 patients suffered from
acute rejection episodes, 1 with urinary tract infection, cyclo-
sporine toxicity, ATN, lymphocyle and urinary leak. In
group Ib, 4 patients suffered from acute rejection episodes,
2 with urinary tract infection, 1 with cyclosporine toxicity,
1 with CMV disease, 1 with ATN, 2 with lymphocyle and
1 with urinary leak.
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Figure 1D S. Stem cell factor (pg/ml) in patients in renal
transplant recipients with chronic allograft dysfunction (Group
Ia), stable allograft function (Group Ib) and in controls (Group
II).
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Figure 1C U. Alkaline phosphatase (lmol/min) in patients in
renal transplant recipients with chronic allograft dysfunction
(Group Ia), stable allograft function (Group Ib) and in controls
(Group II).
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Table 1 shows that hemoglobin level was signiﬁcantly lower in
both groups of patients than the controls and in group Ia than
group Ib (F= 26.55, P< 0.001).
The blood urea, serum creatinine, CRP, and urinary pro-
tein excretion were signiﬁcantly higher in group 1a patients
(patients with CAN) than group 1b (patients with stable allo-
graft function) and controls. While there was no statistically
signiﬁcant difference between both group 1b and controls
(F= 25.6, P< 0.001), (F= 31.32, P< 0.001) (F= 23.34, P
< 0.001) (F= 17.260, P < 0.001), respectively. Creatinine
clearance and U.ALP were signiﬁcantly lower in patients than
controls and in patients of group Ia than patients of group Ib
(F= 159.52, P< 0.001), (F= 6.230, P= 0.004), respec-
tively. (Figs. 1A–1C)
Table 2 shows that there was a signiﬁcant increase in the
levels of SCF, number of peripheral blood HSCs and MSCs
in both transplanted patient groups than the controls and they
were higher in patients of group Ia than patients of group Ib,
(F= 39.73, P< 0.001), (F= 13.28, P< 0.001), (F= 11.94,
P< 0.001), respectively (Figs. 1D and 1E). Renal hemody-
namic study revealed a signiﬁcant increase in RI and PI withTable 2 Mean ± SD and statistical comparison of serum stem c
mesenchymal stem cells and HSCs/MSCs ratio, resistive index, pulsa
renal blood ﬂow in the studied groups.
Parameters Group Ia Group Ib Group II
SCF (pg/ml) 246.47 ± 72.51 129.67 ± 67.04 47.40 ±
HSCs (cell/lL) 7.20 ± 3.53 4.87 ± 1.96 2.80 ±
MSCs (cell/ lL) 12.27 ± 7.14 8.07 ± 2.31 4.40 ±
HSCs/MSCs ratio 0.64 ± 0.19 0.62 ± 0.23 0.69 ±
RI 0.73 ± 0.07 0.60 ± 0.05 0.59 ±
PI 1.28 ± 0.20 1.08 ± 0.10 1.04 ±
Diameter (mm2) 21.44 ± 4.64 34.89 ± 3.79 37.70 ±
RBF (ml/min) 475.33 ± 108.75 790.00 ± 112.25 862.33 ±
SCF= Stem cell factor, HSCs = hematopoeitic stem cells, MSCs = m
Diameter = renal artery cross sectional area, RBF = Renal blood ﬂow.
Abbreviations as in Table 1.a signiﬁcant decrease in renal artery cross sectional area and
RBF in patients of group Ia than group Ib and controls, insig-
niﬁcant difference was found between group Ib and controls
(Fig. 1F).
3.3. Histopathology results
All biopsies showed picture of CAN. Nine biopsies showed
CAN1a, and 6 biopsies showed CAN1b (according to Banff
classiﬁcation 2011) (See Figs. 2A–2F)
The glomeruli in seven biopsies showed double contour of
the peripheral capillary loops in 25–50% (cg2). Six biopsies
showed an increase in mesangial matrix in 0–25%. 0–25% of
the cortical tubules was inﬁltrated by mononuclear inﬂamma-
tory cells in seven biopsies (t1) and mild to moderate degree of
tubular atrophy (ct1, ct2) was found. Eight biopsies showed 0–
25% interstitial inﬁltration by mononuclear inﬂammatory cells
(i1), mild to moderate degree of interstitial ﬁbrosis (ci1, ci2),
was found in eleven and four biopsies respectively. This was
obviously shown with masson trichrome stain. None of the
biopsies showed evidence of intimal arteritis (v0), while twelveell factor, Peripheral blood count of hematopoietic stem cells,
tility index, cross sectional area of the renal allograft artery and
F P L S D
GIa/GIb GIa/GII GIb/GII
17.71 39.73 <0.001 * * *
0.86 13.28 <0.001 * * *
1.45 11.94 <0.001 * * *
0.28 0.384 0.683 NS NS NS
0.05 29.52 <0.001 * * NS
0.09 13.46 <0.001 * * NS
3.92 66.29 <0.001 * * NS
85.33 60.08 <0.001 * * NS
esenchymal stem cells, RI = resistive index, PI = pulsatility index,
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Figure 1E Hematopoeitic stem cells (HSCs) and Mesenchymal
stem cells (MSCs) (cell/ll) in patients in renal transplant recipients
with chronic allograft dysfunction (Group Ia), stable allograft
function (Group Ib) and in controls (Group II).
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Figure 1F Resistive index (RI) and Pulsatility index (PI) in
patients in renal transplant recipients with chronic allograft
dysfunction (Group Ia), stable allograft function (Group Ib) and
in controls (Group II).
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Figure 2A Correlation between mesenchymal stem cells (cell/uL)
and C-reactive protein (mg/L) in renal transplant patients with
chronic allograft nephropathy (group Ia) and with stable allograt
function (Group Ib).
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Figure 2B Correlation between stem cell factor (pg/ml) and
hematopoietic stem cell (cell/uL) in renal transplant patients with
chronic allograft nephropathy (group Ia) and with stable allograt
function (Group Ib).
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Figure 2C Correlation between hematopoietic stem cells (cell/
uL) and S. C-reactive protein (mg/L) in renal transplant patients
with chronic allograft nephropathy (group Ia) and with stable
allograt function (Group Ib).
240 H.A.M. El Aggan et al.of them displayed ﬁbrous intimal thickening and narrowing of
the included arteries up to 25% (cv1). Three biopsies displayed
ﬁbrous intimal thickening and narrowing of the included arter-
ies 25–50% (cv2). Mild arteriolar hyalinosis was detected in
eight biopsies (ah1). (Fig. 3 {A, B})
Table 3 shows the immunohistochemical results of biopsies
of patients with CAN using CD34, CD133, VEGF and ASMA
antibodies. It ranged from minimal to moderate in distribution
and showed the intensity and distribution of these markers
(glomerular, mesangial, or tubular) (Fig. 3 {C–F}).
3.4. Statistical correlations
The correlations between the different studied parameters in
both groups of patients are present in Tables 4 and 5, and
Fig. 2.
In patients with group Ia there was a positive correlation be-
tween SCF and HSCs (r= 0.643, P= 0.010), also, HSCs were
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Figure 2D Correlation between urinary alkaline phosphatase
(umol/uL) and C-reactive protein (mg/L) in renal transplant
patients with chronic allograft nephropathy (group Ia) and with
stable allograt function (Group Ib).
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Figure 2E Correlation between renal alpha smooth muscle actin
and renal progenitor cells CD133 in renal transplant patients with
chronic allograft nephropathy (group Ia).
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Figure 2F Correlation between renal vascular endothelial
growth factor and renal progenitor cells CD133 in renal transplant
patients with chronic allograft nephropathy (group Ia).
Role of bone marrow-derived stem cells, renal progenitor 241positively correlated withMSCs, S.CRP and creatinine (r= 0.8
77, P< 0.001), (r= 0.651, P= 0.009), (r= 0.668, P= 0.006)respectively. U.ALP was negatively correlated with S. creati-
nine, S.CRP and RI (r= 0.652, P= 0.008), (r= 0.782,
P= 0.001), (r= 0.751, P< 0.001) respectively. The renal
progenitor cells CD133 were positively correlated with CD34
(r= 0.873,P< 0.001) and both were positively correlated with
VEGF (r= 0.600,P= 0.018). (r= 0.722,P= 0.002) and neg-
atively correlated with ASMA (r= 0.612, P= 0.015),
(r= 0.757, P= 0.001) respectively. In group Ib there was a
positive correlation between SCF and HSCs (r= 0.790,
P< 0.001), also, HSCs were positively correlated with MSCs,
S.CRP and. creatinine (r= 0.617, P= 0.014), (r= 0.767,
P= 0.001) (r= 0.799, P< 0.001) respectively. U.ALP was
negatively correlated with S. creatinine, S.CRP and RI
(r= 0.879, P< 0.001), (r= 0.609, P< 0.001) (r= 0.7
56, P= 0.001) respectively.4. Discussion
In the present work, blood urea and creatinine levels were
signiﬁcantly higher in group Ia than Ib and the difference
was insigniﬁcant between group Ib and control groups, but
creatinine clearance was signiﬁcantly lower in group Ia than
Ib and in Ib than control group. This goes with earlier studies
which reported that successful kidney transplantation at the
best transfers patients from chronic kidney disease stage 5
(CKD5) to CKD2 but never normalized GFR.44,45 As
expected CAN group had a signiﬁcant lower GFR than stable
transplanted patients but moreover, the difference between the
two groups beside being statistically signiﬁcant, was of critical
clinical value as the patients were transferred from CKD2 to
CKD3b.
Also hemoglobin level was lower in patient group than con-
trol and lower in patients with CAN than patients without
CAN, this ﬁnding may be attributed to reduction in GFR in
CAN group and the use of immunosuppressant drugs with
or without RAS blockers in transplanted cohort, this was also
shown and explained by Winkelmayer et al.46 this anemia in
patients with CAN was described by Choukroun et al.,47
who also described a good relation between correction of ane-
mia and retarding the progression of CAN, also Winkelmayer
et al.48 described a deﬁnite relation between anemia and
chronic allograft loss.
Urinary protein level was signiﬁcantly higher in group Ia
than group Ib, also it was signiﬁcantly higher in group Ia than
control subjects, while the difference was insigniﬁcant between
group Ib and control group. Proteinuria was correlated nega-
tively with GFR. This result was matched with what was
shown by Fernandez-Fresnedo et al. as they showed in their
work a signiﬁcant increase of proteinuria in transplanted pa-
tients that was also correlated with renal allograft dysfunc-
tion.49 Many other investigators showed the same results
repeatedly over the years.50–55
CRP was signiﬁcantly higher in the CAN group than trans-
planted group with stable renal functions and there was no sig-
niﬁcant difference between the latter group and control
subjects. In concordance to our ﬁndings, Sezer et al.56 and
Fink et al.57 found similar data with elevation of CRP level
in transplant population. Not only in transplant patients but
also in non diabetic CKD there was an increase in CRP as seen
in the study done by Stuveling et al.58 in the absence of any evi-
dence of infection goes with the assumption that there is a
A  
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B  
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Figure 3 Light microscopy of CANIa (A) showing tubular atrophy with interstitial ﬁbrosis (Masson trichrome) (arrows). (B) Fibrous
intimal thickening (FIT), tubular atrophy (TA), and interstitial ﬁbrosis (IF). Immunostaining (C) with anti CD 133 displayed nuclear
deposits within the mesangium (arrow) (D) with anti CD34 demonstration positive membranous staining of hemopoeitic stem cell (HSC)
around blood vessels (E) with anti vascular endothelial growth factor (VEGF) showing positive endothelial cytoplasmic staining (arrow)
(F) with anti alpha smooth muscle actin (ASMA) demonstrating positive membranous staining within the interstitium with peri-tubular
and peri-vascular distribution (arrow).
242 H.A.M. El Aggan et al.persistent state of micro inﬂammation in patients who develop
CAN.
Urinary alkaline phosphatase was signiﬁcantly less in pa-
tients who developed CAN than patients without CAN, and
control subjects, this could be explained by signiﬁcant degree
of tubular atrophy in patients who developed CAN producing
less amount of alkaline phosphatase in response to injury due
to less tubular cell mass in a way that resemble liver enzymes in
cirrhosis. Although the data of urinary alkaline phosphatase in
kidney transplant are scarce, yet in another kidney disease
model viz diabetic nephropathy, it was shown that urinary
alkaline phosphatase can mark early proximal tubular injury
even preceding the appearance of micro albuminuria.59
In the present work the levels of SCF in the peripheral
blood of the patient group are signiﬁcantly higher than control
and regarding the subgroups of renal transplantation, its level
in the patients with CAN was signiﬁcantly higher than patients
without CAN. A decade ago, a putative role for SCF in the
pathogenesis of various forms of kidney disease progression
was observed in several studies.60,61 On the other hand, other
studies suggested a regenerative role of SCF in renal diseases.62
In concordance with the ﬁnding of previously mentioned stud-ies, in the present study SCF was positively correlated with
each of HSC markers (CD34, CD117 and CD45), MSC mark-
ers (CD106) in serum of both transplanted groups.
In the present work, stem cell markers were upregulated in
transplanted patients and even more in patients who developed
CAN in the absence of any other inﬂammatory condition that
explains this ﬁnding. This may support the assumption that
stem cells and SCF upregulation in patients with CAN may
point out their potential role in the process of repair of a fail-
ing graft. On the contrary to this view, it may represent a
mechanism by which ongoing ﬁbrosis of the graft causes pro-
gressive deterioration of its function. Many studies have sup-
ported the former concept both in experimental and human
models, in both kidney transplantation and other forms of kid-
ney diseases. On the other hand other studies advocate for the
latter view.
Imasawa et al.63 clariﬁed the role of BM derived stem cells
in mesangial cell regeneration in a rat model. Similarly Ito et
al.64 proved the upregulation and migration of CD45 + ve
BM-derived stem cells for glomerular repair in a rat model
after anti Thy-1 glomerulonephritis and they concluded that
the bone marrow can give rise to mesangial cells in vivo.
Table 3 Frequencies of immunohistochemical expression of CD133+, CD34+ cells, vascular endothelial factor, alpha-smooth muscle
actin and renal ﬁbrosis in renal biopsies of patients with chronic allograft dysfunction.
Immunohistochemical Number of patients Percentage of patients
CD133+
Minimal 0 0
Mild 7 53.3%
Moderate 8 46.7%
CD34+
Minimal 0 0
Mild 11 73.3%
Moderate 4 26.7%
VEGF
Minimal 0 0
Mild 10 66.7%
Moderate 5 33.33%
ASMA
Minimal 1 6.7%
Mild 11 73.3%
Moderate 3 20%
Fibrosis
Minimal 0 0%
Mild 8 53.3%
Moderate 7 46.7%
VEGF= Vascular endothelial growth factor.
ASMA= Alpha smooth muscle actin.
Table 4 Statistical correlation between some of the studied parameter in renal transplant recipient with chronic allograft dysfunction.
Variable S. Cr Cr Cl U. Pr CRP U. ALP S. SCF HSCs MSCs
S. Cr r
P
Cr Cl r 0.955*
P <0.001
U. Pr r 0.521* 0.554*
P 0.046 0.032
S. CRP r 0.910* 0.829* 0.528*
P <0.001 <0.001 0.043
U. ALP r 0.652* 0.658* 0.265 0.782*
P 0.008 0.008 0.340 0.001
S. SCF r 0.838* 0.773* 0.457 0.854* 0.764*
P 0.000 0.001 0.087 <0.001 0.001
HSCs r 0.668* 0.630* 0.625* 0.651* 0.432 0.643*
P 0.006 0.012 0.013 0.009 0.108 0.010
MSCs r 0.816* 0.832* 0.714 0.763* 0.507 0.669* 0.877*
P <0.001 <0.001 0.003 0.001 0.053 0.006 <0.001
RI r 0.577* 0.534* 0.549* 0.768* 0.751* 0.724* 0.546* 0.530*
P 0.024 0.040 0.034 0.001 <0.001 0.002 0.035 0.042
Abbreviations as in Tables 1 and 2.
Role of bone marrow-derived stem cells, renal progenitor 243Sugimoto et al.65 reported a signiﬁcant clinical and histo-
logical improvement in cases of Alport syndrome who were
treated with stem cells and stated that their data conﬁrm that
BM derived stem cells could have a positive role in renal
regeneration.
Semedo et al.66 studied the effect of MSCs on renal inﬂam-
mation and ﬁbrosis in a rat model of chronic renal failure and
their results suggested that MSC therapy can indeed modulate
the inﬂammatory response that follows the initial phase ofchronic renal injury. The immunosuppressive and remodeling
properties of MSCs may be involved in the decreased ﬁbrosis
in the kidney. Marina Morigi et al.67 studied the effect of
MSCs derived from male mice in treating cisplatin induced
ARF in female mice and their results offered a strong case
for exploring the possibility that mesenchymal stem cells by
virtue of their renotropic property and tubular regenerative
potential may have a role in the treatment of acute renal failure
in humans.
Table 5 Statistical correlation between some of the studied parameter in renal transplant recipient with stable allograft function.
Variable S. Cr Cr Cl U. Pr CRP U. ALP S. SCF HSCs MSCs
S. Cr r
P
Cr Cl r 0.935*
P <0.001
U. Pr r 0.848* 0.874*
P <0.001 <0.001
S. CRP r 0.762* 0.822* 0.750*
P <0.001 <0.001 <0.001
U. ALP r 0.879* 0.892* 0.714* 0.609*
P <0.001 <0.001 0.003 <0.001
S.SCF r 0.618* 0.778* 0.678* 0.735* 0.726*
P 0.014 <0.001 0.005 0.002 0.002
HSCs r 0.799* -0.834* 0.736* 0.767* 0.834* 0.790*
P <0.001 <0.001 0.002 0.001 <0.001 <0.001
MSCs r 0.546* 0.728* 0.653* 0.526* 0.687* 0.895* 0.617*
P 0.035 0.002 0.008 0.044 0.005 <0.001 0.014
RI r 0.893* 0.779* 0.787* 0.668* 0.756* 0.530* 0.598* 0.506
P <0.001 <0.001 <0.001 0.007 0.001 0.042 0.019 0.054
Abbreviations as in Tables 1 and 2.
244 H.A.M. El Aggan et al.Kunter et al.68 studied the reparative role of MSCs in a rat
model of glomerulonephritis through infusion of MSCs in the
rat renal artery after induction of GN, then detection of these
intraglomerular cells and correlation with glomerular healing.
Acute renal failure was ameliorated by MSC injection into the
left renal artery on day 2 after disease induction. Again, MSC
led to more rapid recovery from mesangiolysis, increased
glomerular cell proliferation, and reduction of proteinuria by
28%.
Chen et al.69 studied the ability of kidney derived MSCs to
produce endothelial and smooth muscle like cells under the
inﬂuence of angiogenic factors as VEGF both in vivo and
in vitro and stated that kidney mesenchymal stem cells are
capable of differentiation toward endothelial and smooth mus-
cle cell lineages in vitro and in vivo, support new blood vessel
formation in favorable conditions and promote functional
recovery of an ischemic kidney.
Togel et al.70 studied the positive effect of MSC infusion in
the setting of AKI and concluded that MSC and endothelial
cells interact and that these interactions are likely responsible,
at least in part, for the kidney-protective effects of MSC in
AKI, mediated by complex paracrine actions that are able to
signiﬁcantly protect and regenerate the damaged vasculature
in AKI.
Wide spread distribution of CD133 positivity was detected
in nearly all histopathology domain of the, interstitial and
tubular) might point out to the potential reparative role of
renal progenitor cells in CAN. This goes with the ﬁnding of
Ronconi E et al. in a different model of kidney disease.71
CD34 was detected obviously around blood vessels and
within the interstitium, this exceeds the limits of renal endothe-
lial cells and presents the upregulation of HSCs and their hom-
ing in the transplanted kidney in patients with chronic
allograft injury and may be a part of the setup of renal repair.
Di Marco et al.72 detected an increased level of endothelial
progenitor cells which are CD34 + ve, and VEGFR2 + ve
in renal transplant patients who had endothelial dysfunction
than matched controls and assumed that it has a reparative
role. BM derived stem cells have been reported by Rookmaa-ker et al.73 to contribute to glomerular endothelial repair fol-
lowing thrombotic microangiopathy.
VEGF is a known endothelial marker that upregulates in
situations where there is neoangeogenesis. Rate of VEGF in
different clinical situations is controversial whereas it might
be considered a harmful player in cases of cancer metastasis,74
and proliferative diabetic retinopathy,75 to the extent that spe-
ciﬁc anti-VEGF mono clonal antibodies,76 are now in clinical
utility for such condition, Its role in situation like kidney dis-
eases is to be more clariﬁed.
In this work VEGF was located by immunohistochemistry
in endothelial cytoplasmic distribution both in peritubular
capillaries as well as blood vessels whether this represents a
normal ﬁnding or an up regulation of the level of its expression
due to CAN is still unclear and is an interesting point to be fur-
ther studied
The positivity of ASMA in this group of patients is an ex-
pected ﬁnding as the latter is known to be highly associated with
ﬁbrosing situations in different models of kidney diseases.77
Both RI and PI were signiﬁcantly higher in group Ia
than group Ib, also they were signiﬁcantly higher in group Ia
than control subjects, while the difference was insigniﬁcant
between group Ib and control group. Elster et al.78 suggested
that elevated RI is an early predictor of histologically relevant
CAN, possibly a result of undergoing vasculopathy, and stated
that early evidence of CAN may allow for a targeted change in
therapy before clinically signiﬁcant injury. Ultrasonography
should become a routine part of a transplantation clinic
evaluation.
Radermacher et al.79 studied 122 kidney allograft recipients
regarding Doppler parameters and suggested that a Doppler
ultrasonographic study performed three or more months after
transplantation can predict long-term allograft outcomes.
Their data also suggest that longitudinal Doppler studies
may be useful in monitoring interventions such as different
immunosuppressive protocols or in comparing the capability
of various antihypertensive drugs to improve allograft out-
comes. Such studies may reduce the need for sequential renal
biopsies, with their associated risks. However, an increased
Role of bone marrow-derived stem cells, renal progenitor 245resistance index could mean acute vascular rejection with end-
arteritis, chronic allograft nephropathy, or both. Only a renal
biopsy can distinguish among these conditions.
In this study RI and PI were correlated negatively with cre-
atinine clearance, the same was shown by Nezami et al.80 who
studied the correlation of Doppler parameters to renal allograft
dysfunction after kidney transplantation in 273 kidney allograft
recipients and found that there is a strong correlation between
the PI and PI that allow physicians to use each of them instead
of the other in patients with a kidney allograft undergoing
Doppler ultrasound., and stated that there is a signiﬁcant corre-
lation between theseDoppler ultrasound indexes and serum cre-
atinine level. Doppler ultrasound can be used as a tool to predict
kidney function in association with serum creatinine, but its
applicability depends heavily on the operator’s skill.
In conclusion, upregulation of stem cell markers in trans-
planted patients and even more in patients who developed
CAN in the absence of any other inﬂammatory condition that
explain this ﬁnding may support the assumption that stem cells
and SCF upregulation in patients with CAN might point out
their potential role in the process of repair of a failing graft.References
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